The August issue of the Journal of the Neurological Sciences Vol 487
Issue highlights
Research Article (Open Access)
Real-world timing of early anticoagulation therapy in intracerebral hemorrhage patients with atrial fibrillation: An observational studyAbe et al. Published online: May 5, 2026 The efficacy of anticoagulation therapy in patients with intracerebral hemorrhage (ICH) and concomitant atrial fibrillation (AF) remains controversial. As the decision to resume anticoagulation therapy remains debated, the optimal timing for resumption has rarely been investigated. This study retrospectively explored the timing of anticoagulation initiation using data from a multicenter registry of eight stroke centers. |
|
Research Article
Predictive value of CHA2DS2-VASc score for long-term outcomes after large vessel occlusion in patients with non-valvular atrial fibrillationOhara et al. Published online: May 5, 2026 The CHA2DS2-VASc score assesses the stroke risk in patients with atrial fibrillation (AF). This study determined the predictive value of the CHA2DS2-VASc score for long-term outcomes after acute ischemic stroke (AIS) with large vessel occlusion (LVO) in patients with AF. |
|
Review Article
Chimeric antigen receptor T-cell therapy in neurological disorders: Emerging applications, evidence, and challengesLuo et al. Published online: May 7, 2026 Originally developed for blood cancers, CAR T-cell therapy represents a major shift in neurology from lifelong immunosuppression to full immune reset. Early studies show promising, sustained remission in antibody-mediated diseases like myasthenia gravis, multiple sclerosis, and NMOSD. However, its use in immune-mediated neuropathies is still largely theoretical, and it cannot target genetic or metabolic neuromuscular disorders. Broader adoption will depend on strict patient selection, neurologist-led trials, and finding ways to safely manage serious side effects like immune effector cell–associated neurotoxicity syndrome (ICANS). |
|
Review Article (Open Access)
Mortality associated with facioscapulohumeral muscular dystrophy: A systematic literature reviewLi et al. Published online: May 7, 2026 Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic disorder characterized by progressive muscle weakness and atrophy. The onset of FSHD ranges between infancy and adulthood, initially affecting the face, shoulders, and upper arms. Limited evidence exists regarding the disease characteristics and associated mortality.
|
|
Web design by Tribal Systems